Unbounded Dedication to Patients

Learn More

About Adastra

Adastra is a privately held pharmaceutical company based in San Diego, California and Princeton, New Jersey. The company focuses upon the clinical and commercial development of proprietary medicines for the treatment of cancer. The Adastra development programs are guided by world-class key opinion leaders and advisors. The lead candidate, zotiraciclib, is currently in Phase 1b development in cancers with Myc overexpression. The core management team has successfully transitioned their years of experience developing oncology drugs in large pharmaceutical companies into the entrepreneurial biotech environment. Adastra is backed by a syndicate of premier life sciences investors, including: Domain Associates, Lee’s Pharma, Morgenthaler Ventures, ProQuest Investments, and RusnanoMedInvest.


Zotiraciclib Mechanism

Zotiraciclib potently inhibits cyclin-dependent kinase 9 leading to apoptotic effect and modulation of the cell cycle. Zotiraciclib blocks the activity of RNA polymerase II, leading to depletion of the key cancer cell survival protein, c-Myc. In glioblastoma cell lines and in vivo models, zotiraciclib has demonstrated broad anti-tumor activity.


Overexpression of the Myc oncogene has been reported in >80% of glioblastomas. In vitro and in vivo glioma models have demonstrated that inhibition of Myc reduced proliferation and increased apoptosis.

Two zotiraciclib clinical trials are ongoing in glioblastoma.
Link: NCT02942264
Link: NCT03224104

Hepatocellular Carcinoma

Overexpression of the Myc oncogene has been reported in 40-60% of hepatocellular tumors and is associated with poor prognosis in this patient population.

A zotiraciclib clinical trial in hepatocellular carcinoma will initiate in 1Q 2018 in Hong Kong.

Our Team

Scott Megaffin

Chief Executive Officer

Tracy Lawhon

Chief Operating Officer

Lynne Rollins

Chief Financial Officer

Stuart Gallant

Head, Pharmaceutical Manufacturing

Rosemary Mazanet

Strategic Advisor

Kristan Meetze

Head, Tumor Biology

Jillian Chapas-Reed, MS

Vice President, Clinical Operations

Board of Directors

Mauro Bove

Lee’s Pharmaceutical Holdings Inc.

Ralph E. (Chris) Christoffersen

Partner, Morgenthaler Ventures

Thomas M. Estok

President and Chief Executive Officer, Dracen Pharmaceuticals

Scott Megaffin

Chief Executive Officer, Adastra Pharmaceuticals

Dennis G. Podlesak

Partner, Domain Associates

Alain Schreiber

Managing Partner, ProQuest Investments

Eckard Weber

Partner, Domain Associates

Grigory Borisenko, PhD

Investment Director, RMI


12481 High Bluff Drive
Suite 150
San Diego, CA 92130

202 Carnegie Center
Suite 104
Princeton, NJ 08540

Telephone: (760) 208-6900